Soligenix, Inc. Banner Image

Soligenix, Inc.

  • Ticker SNGX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Soligenix, Inc. Logo Image
  • 11-50 Employees
  • Based in Princeton, New Jersey
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Their Specialized BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, their first-in-class innate defense regulatorMore (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).
4.7 / 5.0 (254)

Soligenix, Inc. reports have an aggregate usefulness score of 4.7 based on 254 reviews.

Soligenix, Inc.

Most Recent Annual Report

Soligenix, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

Soligenix, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!